News

View By:
Date Title

Identification of an Internalizing Cancer Target for Novel Antibody Drug Conjugate Development by A&G Pharmaceutical and Precision Antibody Researchers

Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study about the identification of Prostaglandin F2 receptor negative regulator as a cancer cell surface target and the isolation of internalizing antibody for antibody drug conjugate development.

ARV-7 Press Release

Precision Antibody is pleased to announce the recent article published in Cancers 2020, by Konig et al entitled “Expression of AR-V7 (androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients”.

A&G Pharmaceutical, Inc. and Precision Antibody Develop Sandwich ELISA for Metastatic Breast Cancer Clinical Studies

A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed mouse monoclonal antibodies (mAbs) against COVID-19 antigens; Spike protein S1 and nucleocapsid protein (N-protein).

Covid-19 Antibody Development at Precision Antibody

A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed mouse monoclonal antibodies (mAbs) against COVID-19 antigens; Spike protein S1 and nucleocapsid protein (N-protein).
How can we help?
Design Your Project
Request A Quote
Purchase antibodies